Assessment of patient-reported outcomes at 24 weeks of treatment with tralokinumab for atopic dermatitis: a multicentric real-life experience

J Dermatolog Treat. 2023 Dec;34(1):2285243. doi: 10.1080/09546634.2023.2285243. Epub 2023 Nov 20.

Authors

Silvia Ferrucci¹, Francesca Barei¹, Simona Tavecchio², Angelo V Marzano^{1

2}, Martina Zussino¹, Luigi Naldi^{3

4}, Elena Pezzolo^{3

4}

Affiliations

¹ Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
² Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
³ Dermatology Unit, Ospedale San Bortolo, Vicenza, Italy.
⁴ Study Centre of the Italian Group for the Epidemiologic Research in Dermatology (GISED), Bergamo, Italy.

PMID: 37985495
DOI: 10.1080/09546634.2023.2285243

No abstract available

MeSH terms

Antibodies, Monoclonal / therapeutic use
Dermatitis, Atopic* / drug therapy
Humans
Patient Reported Outcome Measures
Severity of Illness Index
Treatment Outcome

Substances

tralokinumab
Antibodies, Monoclonal